Tag: CLL

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


targeted15

Therapeutic options for Treatment-Naïve Chronic Leukocytic Leukemia

During a virtual Targeted Oncology Case-Based Roundtable event, Daniel O. Persky, MD, reviewed the case of a 61-year-old patient with chronic lymphocytic leukemia.

Visit website
Immunotherapy Web Featured Images 109

Browse this week's featured selection of scientific publications

A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are are a few highlights from this week.

Visit website
onclive6

Cirmtuzumab/Ibrutinib Shows Encouraging Clinical Activity, Safety in MCL and CLL

  Mar 03 2021 Tagged mAbs, MCL, CLL

Hun Ju Lee, MD, discusses a phase 1/2 study evaluating cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma or chronic lymphocytic leukemia.

Visit website
Onclive18

Ianalumab/Ibrutinib Combo Shows Promising Activity in CLL

  Mar 03 2021 Tagged mAbs, CLL

Kerry A, Rogers, MD, discusses the rationale behind the phase 1b study of VAY736 combined with ibrutinib in patients with chronic lymphocytic leukemia and the next steps for this research.

Visit website
Immunotherapy Web Featured Images 96

Ianalumab add-on therapy in CLL patients receiving ibrutinib

  Feb 03 2021 Tagged CLL, mAbs

Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, discusses a Phase Ib trial (NCT03400176) of ianalumab plus ibrutinib in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib therapy. Ianalumab (VAY736) is an anti-BAFF-R monoclonal antibody that causes antibody-dependent cellular cytotoxicity of B-cells.

Visit website
vjhemonic5

Updates at ASH in CLL: U2 and ublituximab

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses his excitement for updates from the UNITY-CLL study which will be presented at ASH 2020.

Visit website
Immunotherapy Web Featured Images 45

ASH 2020 | TRANSCEND CLL 04: 18-month follow-up of liso-cel for R/R CLL

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of a trial (NCT03386513) of IMGN632, a novel antibody-drug conjugate (ADC), in relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), a setting with poor outcomes and minimal treatment options.

Visit website
Immunotherapy Web Featured Images 33

iwCAR-T meeting 2020: featured sessions

  Nov 26 2020 Tagged CAR-T, NHL, ALL, AML, MM, CLL

During iwCAR-T 2020, some of the world’s leading clinical researchers shared their perspectives on how to place our evolving understanding in a clinical context and thereby optimize clinical care.

Visit website